Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update

Summary by AI BETAClose X

Vivoryon Therapeutics N.V. reported a net loss of EUR 3.4 million for the first half of 2026, a decrease from EUR 5.5 million in the same period of 2025, with cash and cash equivalents standing at EUR 2.4 million as of June 30, 2026. The company maintained its financial guidance, expecting current cash to fund operations into Q4 2026, and is actively pursuing strategic partnerships, including advanced term sheet negotiations for a potential licensing agreement for its varoglutamstat program in kidney disease. Research and development expenses decreased to EUR 1.7 million and general and administrative expenses fell to EUR 1.7 million in H1 2026 compared to H1 2025.

Disclaimer*

UK 100

Latest directors dealings